The menstrual cycle may not be limited to the endometrium but also may impact intestinal permeability.

Chutima Roomruangwong, M.D.(a), André F. Carvalho, M.D., Ph.D (b,c), Michael Maes, M.D., Ph.D. (a,f,g)

a) Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

b) Department of Psychiatry, University of Toronto, Toronto, ON, Canada;

c) Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada;

f) Department of Psychiatry, Medical University Plovdiv, Plovdiv, Bulgaria.

g) IMPACT Research Center, Deakin University, Geelong, Australia.

Corresponding author:

Prof. Dr. Michael Maes, M.D., Ph.D.

IMPACT Strategic Research Center

Barwon Health

Deakin University

Geelong, Vic

Australia

dr.michaelmaes@hotmail.com

http://scholar.google.co.th/citations?user=1wzMZ7UAAAAJ&hl=th&oi=ao

Abstract

Objective: To examine associations between IgA responses to Gram-negative gut-commensal bacteria and peri-menstrual symptoms and sex hormone levels during the menstrual cycle in women with and without premenstrual symptoms.

Methods: Forty women aged 18-45 years completed the Daily Record of Severity of Problems (DRSP) during all 28 consecutive days of the menstrual cycle. We assayed, in plasma,, IgA responses to 6 Gram-negative bacteria, i.e. *Hafnei alvei, Pseudomonas aeruginosa, Morganella morganii, Klebsiella pneumoniae, Pseudomonas putida* and *Citrobacter pylori*, progesterone and oestradiol at days 7, 14, 21 and 28 of the menstrual cycle.

Results: Significant changes in Δ (actual minus one week earlier) IgA to LPS of the 6 Gram-negative bacteria during the menstrual cycle were observed with peak IgA levels at T4 (day 28) and lows at T1 or T2 (day 7 or 14). The Δ IgA changes in *H. alvei*, *M. Morganii, P. putida* during the menstrual cycle were significantly and positively associated with changes in the total DRSP score, and severity of physio-somatic, anxiety and breast-craving, but not depressive, symptoms. The changes in IgA responses to LPS were largely predicted by changes in progesterone and steady-state levels of progesterone averaged over the luteal phase.

Discussion: Menstrual cycle-associated changes in IgA directed against LPS and by inference bacterial translocation may be driven by effects of progesterone on transcellular, paracellular and vascular pathways thereby contributing to the severity of physio-somatic and anxiety symptoms as well as fatigue, breast swelling and food cravings.

Key words: premenstrual syndrome, depression, anxiety, fatigue, neuro-immune, progesterone

Introduction

Premenstrual syndrome (PMS) is defined as a constellation of physical, emotional, and/or behavioral symptoms appearing during the luteal phase of the menstrual cycle and improving after the onset of menses (Deuster et al., 1999; Dickerson et al., 2003). However, there is no consensus definition for PMS and different diagnostic criteria have been proposed (see Table 1). The American College of Obstetricians and Gynecologists (ACOG) proposed that women with PMS must have at least one affective and one physical symptom appearing five days prior to menses for at least three menstrual cycles (American College of Obstetricians and Gynecologists, 2014). Moreover, the symptoms must be relieved within 4 days after the onset of menses without recurrence until at least day 13 of the menstrual cycle (American College of Obstetricians and Gynecologists, 2014). Another gold standard method used to diagnose PMS includes measurement of the Daily Record of Severity of Problems (DRSP): women with a total DRSP score ≥ 70 on day -5 to -1 of menses and having at least a 30% difference between pre- and postmenstrual scores are diagnosed with PMS (Biggs and Demuth, 2011; Endicott et al., 2006; Qiao et al., 2012). In a recent study, two new case definitions were identified, namely 1) peri-menstrual syndrome (PeriMS), which refers to women with increasing DRSP ratings during the peri-menstrual period (day 1+ day 2 + day 24 to 28); and 2) Menstrual Cycle Associated Symptoms (MCAS), which delineates women with increased DRSP ratings all over the menstrual cycle (Roomruangwong et al., 2019). Furthermore, we verified that the diagnosis of PMS according to Biggs and Demuth (2011) as well as the diagnoses of PeriMS and MCAS, but not the ACOG-based PMS diagnosis, were externally validated by levels of the sex hormones oestradiol and progesterone (Roomruangwong et al., 2019). In addition, a diagnosis of PMS according to Biggs and Demuth (2011) was only predicted by lower steady state levels of progesterone in the luteal

phase, while the PeriMS and MCAS diagnoses were significantly related to both sex hormones (Roomruangwong et al., 2019). Lower steady-state levels of progesterone averaged over the luteal phase coupled with decreasing progesterone levels during the luteal phase also predicted changes in severity of the DRSP as well as alterations in severity of its 4 subdomains, namely a) depressive symptoms; b) fatigue and physio-somatic symptoms; c) increased appetite and craving combined with breast tenderness and swelling; and d) anxiety (Roomruangwong et al., 2019). Therefore, we concluded that the diagnosis of PeriMS comprises the most accurate diagnostic criteria to describe changes in different symptoms dimensions in the periMS period and that the latter are at least in part mediated by sex hormones. Furthermore, it appeared that PeriMS is associated with a relative luteal phase deficiency or corpus luteum deficiency (Roomruanwong et al., 2019).

Recently, evidence indicates that increased translocation of Gram-negative gut commensal bacteria may play a pathophysiological role in major depression (Maes et al., 2008; Maes et al., 2012; Maes et al., 2013a; Martin-Subero et al., 2016; Slyepchenko et al., 2017; Slyepchenko et al., 2016), fatigue and physio-somatic symptoms (Maes and Leunis, 2008; Maes et al., 2014; Maes et al., 2007; Maes et al., 2013b), anxiety/stress (Galley and Bailey, 2014; Gareau et al., 2008; Keightley et al., 2015; Roomruangwong et al., 2017a; Sgambato et al., 2017) and postpartum depression (PPD) (Roomruangwong et al., 2018 ; Roomruangwong et al., 2017b). However, it remains unclear whether bacterial translocation of Gram-negative bacteria could play a role in PMS or PeriMS and its four symptom domains.

This hypothesis is conceivable since sex hormones may modulate gut permeability (Edwards et al., 2017). Furthermore, studies in pregnancy and postpartum, which are periods of dramatic changes in sex-hormonal state, have reported altered gut functions and bacterial composition (Brantsaeter et al., 2011; Koren et al., 2012). These hormonal changes may

affect gut contractility thereby increasing gut transit time (Mayer et al., 2014), which may constitute an adaptive response to allow a better absorption of nutrients during pregnancy (Edwards et al., 2017). Furthermore, pregnancy is accompanied by decreased gut permeability and a lowered bacterial translocation as indicated by significantly decreased IgA responses to Gram-negative bacteria, suggesting that pregnancy (with relatively high levels of estrogen and progesterone) could attenuate bacterial translocation (Roomruangwong et al., 2017a; Roomruangwong et al., 2017b). Another study found an increased susceptibility to *Listeria monocytogenes* infection during pregnancy leading to adverse obstetrics outcomes including preterm delivery or stillbirth, which were partly modulated by elevated estrogen and progesterone levels (Garcia-Gomez et al., 2013). In patients with irritable bowel syndrome (IBS), sex hormones may affect peripheral and central regulatory processes of the brain-gut axis, leading to alterations in visceral sensitivity, intestinal barrier function, and immune activation of intestinal mucosa (Mulak et al., 2014). Cyclical changes of ovarian hormones during the menstrual cycle can arguably modulate gastrointestinal (GI) functions including small intestinal transit, gastric emptying, and mucosal blood flow (Heitkemper et al., 2003; Longstreth et al., 2006). Lowered levels of ovarian hormone levels during menses are associated with exacerbations of GI symptoms including abdominal discomfort, bowel habit changes, and bloating (Moore et al., 1998; Mulak and Taché, 2010; Whitehead et al., 1990). However, there are no data whether changes in sex hormones during the menstrual cycle are associated with increased bacterial translocation.

Hence, the current study was carried out to examine whether increasing plasma IgA levels to LPS of Gram-negative bacteria during the menstrual cycle could be associated with the pathophysiology of pre- or perimenstrual syndrome and whether those associations could be related to alterations in sex hormones during the menstrual cycle.

Methods

Participants

Forty female participants aged 18-45 years were recruited by word of mouth at the King Chulalongkorn Memorial Hospital during the period of April-May 2018, including twenty women with subjective complaints of PMS and 20 women without such complaints. Participants comprised hospital's staffs or friends/relatives of hospital's staffs and women accompanying patients to the hospital. Inclusion criteria were: 1) women aged 18-45 years; 2) having a regular menstrual cycle with a cycle length of 27-30 days during the past year; 3) being able to read and write in Thai; 4) willing to have 4 blood samples drawn at day 7 (T1), day 14 (T2), day 21 (T3) and day 28 (T4) of the menstrual cycle; and 5) able to complete the DRPS ratings for all consecutive days of the menstrual cycle. Exclusion criteria for both groups were: 1) those with a life-time history of psychiatric illness (including major depression, bipolar disorder, schizophrenia and obsessive compulsive disorder); 2) those with a history of medical illness, including diabetes type 1, and autoimmune/immune-inflammatory disorders (including rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis); 3) pregnant women or women who are currently using hormonal contraceptive agents; and 4) women who are currently using any psychotropic medications. The study was approved by the Ethics Committee of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (IRB No.611/60, COA No. 1111/2017). Written informed consent was obtained from all participants prior to the study.

Clinical assessments

All participants were requested to complete a demographic and clinical data questionnaire, i.e., menstrual information, age, education, height, weight, a history of substance use, and life style, and they were evaluated by an experienced psychiatrist before

enrollment in the study to rule out other medical and/or psychiatric conditions. All participants completed the Daily Record of Severity of Problems (DRSP) during all consecutive days of their menstrual cycle starting on day 1 of menses to assess the severity of PMS symptoms. The DRSP consists of 21 items + 3 functional impairment items commonly used to assess PMS (Endicott et al., 2006). All items are rated from 1 to 6 (1 = not at all, 2 = minimal, 3 = mild, 4 = moderate, 5 = severe, 6 = extreme). The DRSP is a self-report instrument that rates both the "presence" and "severity" of premenstrual symptoms and that can be used to reliably screen for a DSM-IV diagnosis of premenstrual dysphoric disorder (PMDD) (Biggs and Demuth, 2011). The presence of PMS was considered when the total DRSP score was ≥ 70 on day -5 to -1 of menses and when there was a 30% difference between premenstrual (day -5 to -1) and postmenstrual (day 6-10) scores (Biggs and Demuth, 2011; Endicott et al., 2006; Qiao et al., 2012). In addition, participants were also categorized in those who had PeriMS with increased DRSP ratings during the peri-menstrual period (day 1+ day 2 + day 24 to 28) and MCAS (Roomruangwong et al., 2019). We also computed scores of the four subdomains of the DRSP, namely a) depressive dimension; b) physio-somatic component; c) increased appetite and craving combined with breast tenderness and swelling; and d) anxiety dimension (Roomruangwong et al., 2019).

Assays

In all women, we sampled fasting blood at 8.00 a.m. at T1, T2, T3 and T4 for the assay of IgA directed to Gram-negative bacteria, oestradiol and progesterone. We described in detal elsewhere the assay to detect IgA antibodies directed to Gram-negative bacteria (Roomruangwong et al., 2017). Briefly, LPS derived from Gram-negative bacteria were assayed, namely *Hafnia alvei, Klebsiella pneumonia, Morganella morganii, Pseudomonas aeruginosa,* Citrobacter koseri and *Pseudomonas putida.* Polystyrene 96-well plates (NUNC)

were coated with 200 µl solution containing bacterial components at 4 µg/ml in 0.05 M carbonate buffer at pH 9.6. Well plates were incubated at 4 ℃ for 16 h under agitation. Then, we added 200 µl blocking solution (PBS, Tween 20 0.05%, 5 g/l BSA) for 1 h and placed at 37 ℃. Following two washes with PBS, plates were filled up with 100 µl of sera diluted at 1:1000 in the blocking buffer A (PBS, 0.05% Tween 20, 2.5 g/l BSA) and incubated at 37 ℃ for 105 minutes. After three washes with PBS-0.05% Tween 20, plates were incubated at 37 ℃ for 1 h with peroxidase-labeled anti-human IgA secondary antibodies diluted respectively at 1: 15,000 and 1: 10,000 in the blocking buffer (PBS, 0.05% Tween 20, 2.5 g/l BSA). Afterwards, plates were washed three times with PBS-0.05%Tween 20, and incubated with the detection solution for 10 min in the dark. Chromogen detection solution (Tetramethylbenzedine) was used for the peroxidase assay at 16.6 ml per liter in 0.11 M sodium acetate trihydrate buffer (pH 5.5) containing 0.01% H_2O_2. The reaction was stopped with 25 µl 2-N HCl. After addition of stop solution (H_2SO_4 or HCl), the obtained, proportional absorbance in the tested sample (compared to established concentration of respective antibodies), was measured at 450 nm with one alpha of correction at 660 nm.

The methods to assay both sex hormones were also described in detail previously (Roomruangwong et al., 2019). In brief, we used an immunoassay for the quantitative determination of estradiol and progesterone using Cobas® 601. For estradiol, the 2 steps of assay included: 1) first incubation: incubating the sample (25 µL) with two estradiol‑specific biotinylated antibodies, immune-complexes are formed, the amount of which is dependent upon the analyte concentration in the sample; 2) second incubation: after addition of streptavidin-coated microparticles and an estradiol derivative labeled with a ruthenium complex, the still-vacant sites of the biotinylated antibodies become occupied, with formation of an antibody-hapten complex. The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin, and the reaction mixture is aspirated into the measuring

cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier. Precision was determined using Elecsys reagents, samples and controls in a protocol (EP5-A2) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84) with the intra-assay CV value of 1.2%. For progesterone, the 2 steps of assay included: 1) first incubation: incubating the sample (20 μL) with a progesterone specific biotinylated antibody, immunocomplexes are formed, the amount of which is dependent upon the analyte concentration in the sample; 2) second incubation: after addition of streptavidin-coated micro particles and an progesterone derivative labeled with a ruthenium complex, the still vacant sites of the biotinylated antibodies become occupied, with formation of an antibody-hapten complex. The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin, and the reaction mixture is aspirated into the measuring cell where the micro particles are magnetically captured onto the surface of the electrode. Unbound substances are also removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier. Results are determined via a calibration curve which is instrument specifically generated by 2-point calibration and a master curve provided via the reagent barcode. Precision was also determined using Elecsys reagents, samples and controls in a protocol (EP5-A2) of the CLSI (Clinical and Laboratory Standards Institute) as in estradiol: 2 runs per day in duplicate each for 21 days (n = 84) with an intra-assay CV value of 2.3%.

Statistics

We used analysis of contingency tables (χ^2 test) and analysis of variance (ANOVA) to assess associations between categorical variables and differences in continuous variables between diagnostic groups, respectively. Generalized estimating equation (GEE) analysis, repeated measures, was used to check effects of time, diagnosis and time X diagnosis interaction on the IgA levels, while adjusting for age, cycle length, age of menarche and duration of menses. Using GEE analyses, repeated measurements, we also examined the relationships among the IgA levels to Gram-negative bacteria and either the DRSP values over time (T1, T2, T3 and T4) or changes in sex hormones during the menstrual cycle. Furthermore, we used a distributed lag model to predict the DRPS values over time (dependent variable) by lagged (1 week) values of the IgA responses to Gram-negative bacteria and we computed the Δ IgA responses as current IgA values − lagged IgA values obtained 1 week earlier, which denotes the changes in IgA values the last week before blood sampling. We also use steady-state hormonal levels, namely the sum of the z scores of the progesterone hormone levels at T2, T3 and T4 (zT2+T3+T4). Tests were 2-tailed and a p-value of 0.05 was considered for statistical significance. All statistical analyses were performed using IBM SPSS windows version 25. Statistical analyses were conducted in accordance with the International Conference on Harmonisation E9 statistical principles (November 2005).

Results

Demographic and clinical data.

   Table 2 shows the demographic and clinical data in participants with and without PMS. There were no significant differences in age, years of education, age of menarche, cycle length, duration of menses, total DRSP scores and BMI between groups.

Table 3 shows the DRSP score and subscores at the four different time points, T1, T2, T3 and T4. Thus, there were highly significant variations in those scores all over the menstrual cycle with higher total DRSP and physio-somatic scores at T4 compared to the other time points, and higher at T1 compared to T2 and T3, while T3 showed higher scores than T2. In addition, depression scores were higher at T4 than at T2 and T3, at T1 than at T2, while there were no differences between T2 and T3. Breast-craving and anxiety symptoms were higher at T4 than at T1, T2 and T3, while lowest scores were detected at T2.

Menstrual cycle-associated changes in IgA levels to Gram-negative bacteria

In **Table 4** we examine the effects of time on IgA and Δ IgA (that is actual value − value of one week earlier) responses to the Gram-negative bacteria. The data were analyzed using GEE analysis considering effects of time, time X PMS diagnosis (according to the 4 definitions) and PMS diagnosis, while adjusting for age, cycle length, age of menarche and duration of menses. There were highly significant effects of time on the 6 IgA and Δ IgA levels to Gram-negative bacteria. Table 4 shows differences in Δ IgA responses to the 6 Gram-negative bacteria at the 4 different time points of the menstrual cycle. Peak Δ IgA levels for all Gram-negative bacteria were detected at T4. The lowest Δ IgA responses were detected at T1 (for *C. koseri*) or T2 (for all other bacteria). The Δ IgA responses were significantly higher at T4 than at T1, T2 or T3 for *P. putida, H. Alvei, P. aeruginosa* and *M. morganii* and significantly higher at T4 than T1 and T2 for *C. koseri* and *K. pneumoniae*. There were no significant differences between any of the Δ IgA values between T1 and T2. The Δ IgA values at T3 occupied an intermediate position with values which were often significantly different from T2 and T4. **Figure 1** shows the mean Δ IgA values (in z scores) across the 4 time points. As an index of the overall LPS load we computed a z unit weighted composite score, namely the sum of all z Δ IgA values. Table 4 shows that there were highly

significant differences in this overall index with significantly higher values at T4 than the other three time points while the values were higher at T3 than T2 and no differences between T1 and T2 could be established. GEE analyses showed that the effects of time on IgA directed to Gram-negative bacteria were highly significant and that peak levels were obtained at T4 with lows at T2 or T3 (not significantly different) while IgA levels to LPS at T1 occupied an intermediate position. There were no significant effects of diagnosis (using the 4 diagnostic criteria) or the interaction term time X diagnosis on the IgA or Δ IgA to LPS of Gram-negative bacteria. GEE analyses showed that there were significant and positive effects of age on the Δ IgA levels to *H. alvei* (W=17.87, df=1, p<0.001), *K. pneumoniae* (W=4.51, df=1, p=0.034) and *P. aeruginosa* (W=5.46, df=1, p=0.019). There were also significant and positive effects of cycle length on Δ IgA to *H. alvei* (W=5.71, df=1, p=0.017) and *P. putida* (W=7.60, df=1, p=0.006).

Prediction of DRSP symptoms by IgA response to Gram-negative bacteria

Table 5 shows the associations between total DRSP and subdomain scores (as dependent variables) and changes in IgA responses to Gram-negative bacteria during the menstrual cycle (explanatory variables). We used GEE analysis, repeated measures, to analyze these associations and entered the actual measurements of IgA responses as well as the Δ responses in the analyses. We detected that the changes in DRSP were significantly associated with the Δ (but not actual) IgA levels of *H. Alvei, M. morganii* or *P. putida*. We also found significant associations between changes in the severity of fatigue & physio-somatic and breast-craving symptoms with the Δ IgA levels to LPS of the same three bacteria, while changes in Δ IgA responses to *C. koseri* also predicted breast-craving symptoms. Changes in anxiety symptoms were predicted by Δ IgA responses to *H. alvei*.

In addition, we have carried out a second series of GEE analysis whereby we entered Δ IgA responses to LPS together with the lagged progesterone values and the zT2+T3+T4 progesterone scores as explanatory variables (Roomruangwong et al., 2019). Table 5 shows that after considering the effects of both progesterone values, the effects of Δ IgA values on the DRSP and anxiety scores were no longer significant. Nevertheless, the effects of Δ IgA responses to *P putida* on physio-somatic and breast-craving symptoms remained significant. The oestradiol values were not significant in these GEE analyses and the effects of the IgA levels to different bacteria remained significant after introducing oestradiol data.

Associations between IgA responses to Gram-negative bacteria and sex hormones

In **Table 6** we examine the effects of progesterone (explanatory variables) on the Δ IgA levels to Gram-negative bacteria (dependent variables). We used three different progesterone levels, namely the lagged progesterone values, the Δ changes and the steady-state progesterone values averaged over the second part of the cycle (zT2+T3+T4). The Δ changes in *H. alvei, P. putida, C. koseri* and *P. aeruginosa* were significantly associated with the lagged progesterone values (positively), the Δ changes in progesterone (positively) and zT2+T3+T4 (negatively). The Δ IgA responses to *M. morganii* and *K. pneumoniae* were significantly associated with the lagged progesterone data (again positively) and zT2+T3+T4 (again negatively). In addition, another z composite score denoting the ratio between steady-state progesterone / steady-state oestradiol values (computed as z(zT1+zT2+zT3+zT4) progesterone − z(zT1+zT2+zT3+zT4) oestradiol values) was significantly associated (inversely) with the Δ IgA data and could be used instead of the zT1+T2+T3 progesterone scores shown in table 6 (same significance levels).

Also, the IgA response to LPS of Gram-negative bacteria were significantly associated with the lagged progesterone data but the effects of progesterone were markedly

less as compared with the Δ IgA data. Thus, the lagged progesterone levels were significantly associated with the IgA levels to LPS of *C. koseri* (W=5.23, df=1, p=0.022), *P. putida* (W=10.16, df=1, p=0.001), *K. pneumonia* (W=4.36, df=1, p=0.037) and *M. morganii* (W=4.64, df=1, p=0.031), but not *H. alvei* or *P. aeruginosa.*

Discussion

The first major finding of this study is that there are highly significant changes in the 6 IgA levels to Gram-negative bacteria during the menstrual cycle. Overall, peak changes in IgA levels to LPS of all bacteria were observed at T4 (day 28) with lows at T1 (day 7) or T2 (day 14). These results indicate that women exhibit common rhythms in IgA responses to LPS during the menstrual cycle and by inference that changes in LPS load in the plasma and, consequently, in bacterial translocation may ensue during the menstrual cycle. Phrased differently, our findings indicate increased LPS load at the end of the menstrual cycle with a corresponding reduction in LPS load of potentially harmful pathogens after menstruation. In this regard, Profet hypothesized that menstruation may help to clean the vaginal tract of pathogens (Profet, 1993), although in 1993 there was no evidence for elevated pathogen load before menstruation.

To the best of our knowledge there are no previous studies suggesting significant menstrual cycle-associated rhythms in LPS load. Nevertheless, one study demonstrated a relationship between gut microbiota and an irregular menstrual cycle as indicated by a relative *Prevotella*-enriched microbiome, but lower *Bacteroidales* S24-7, *Clostridiales, Ruminococcus* and *Lachnospiraceae* (Sasaki et al., 2018). *Prevotella* is associated with increased gut permeability since it may degrade mucin (Brown et al., 2011), whereas *Clostridiales, Ruminococcus* and *Lachnospiraceae* are butyrate-producing bacteria, which play a role in maintaining gut homeostasis (Hamer et al., 2008; Pryde et al., 2002) through

providing energy sources to intestinal epithelial cells and producing anti-inflammatory effects (Inan et al., 2000). Moreover, decreased mucin production may lead to a micro-inflammatory environment which may be associated with ovulatory disorders (Sasaki et al., 2018) as indicated by recent findings that inflammation may exert a detrimental effect on ovarian follicle growth and ovulation (Boots and Jungheim, 2015).

Secondly, the immune characteristics of the female reproductive tract may share some similarities with those of the gut (Shacklett and Greenblatt, 2011). For example, there are significant differences in microbiota in the female reproductive tract between the phases of the menstrual cycle (Chen et al., 2017). For example, increased presentation of *Lactobacillus species*, *Sphingobium sp., Propionibacterium acnes* and *Pseudomonas sp.* during the proliferative (day 1-14) and secretory (day 15-28) phases, whereas *P. acnes* appeared to be more abundant during the secretory phase. Overall, the proliferative phase appeared to be associated with increased bacterial proliferation when compared to the secretory phase as indicated by higher pyrimidine and purine metabolism, aminoacyl-tRNA and peptidoglycan biosynthesis, whereas during secretory phase, porphyrin, arginine and proline metabolism were increased, as well as the degradation of benzoate, nitrotoluene and biosynthesis of siderophore. Studies in primates also found that vaginal microbial ecologies are highly affected by the menstrual cycle, especially during the estrous phase (Gajer et al., 2012; Keane et al., 1997; Narushima et al., 1997). In humans, high midcycle estrogen levels are associated with increased *Lactobacillus* proliferation (Boskey et al., 2001; Boskey et al., 1999), whereas increased mucosal secretions are associated with growth of *Candida* (Schwebke and Weiss, 2001). High levels of estrogen and progesterone during midcycle are associated with higher stability of microbial communities (Gajer et al., 2012), whereas there is a lower prevalence, intensity and diversity of microbiota during menstruation (Stumpf et al., 2013).

The second major finding of our study is that there were significant associations between the Δ changes in the IgA responses to LPS and the DRSP scores and its four subdomains. Thus, the Δ changes in *H. alvei*, *M. morganii* and *P. putida* were significantly associated with changes in the total DRSP scores, physio-somatic symptoms and breast-craving symptoms, while *H. alvei* was also associated with anxiety. As such the Δ changes in IgA responses to LPS of Gram-negative bacteria are associated with all symptom domains of the DRSP, except depression. Our current findings extent those of previous studies indicating that IgA levels to Gram-negative bacteria are significantly correlated with physio-somatic symptoms in depression and CFS/ME (Maes et al., 2008; Maes et al., 2007). Gut microbiota also influence the host's appetite and food intake by modulating nutrient sensing and appetite and satiety-regulating systems (Huang and Douglas, 2015; Leitao-Goncalves et al., 2017; Turnbaugh et al., 2006; van de Wouw and Schellekens, 2017). In animal studies, essential amino acids and the concerted action of the commensal bacteria *Acetobacter pomorum* and *Lactobacilli* significantly modulate food choice, especially towards amino acid-rich food (Leitao-Goncalves et al., 2017). Studies in patients with anorexia nervosa found significantly lower alpha (within-sample) diversity in taxa abundance between admission and after discharge from hospital when compared to healthy controls, whilst severity of depression, anxiety, and eating problems were associated with the composition and diversity of the intestinal microbiota (Kleiman et al., 2015). There are also profound microbial perturbations in patients with anorexia nervosa with higher levels of mucin-degraders and members of *Clostridium* clusters I, XI and XVIII and lowered levels of the butyrate-producing *Roseburia sp.*, while in anorexia nervosa patients with restrictive and binge/purging subtypes distinct perturbations in microbial community compositions were observed (Mack et al., 2016).

Moreover, the associations found in our study between changes in IgA to LPS of Gram-negative bacteria and breast symptoms may be explained by possible effects of the gut

microbiome on breast symptoms via the modulating effects of estrogen. Plottel and Blaser (2011) proposed the "estrobolome" as the aggregate of enteric bacterial genes whose products are capable of metabolizing estrogens (Plottel and Blaser, 2011). Under normal conditions, estrogens and their metabolites are conjugated in the liver through glucuronidation or sulfonation to allow for biliary excretion (Zhu and Conney, 1998). Conjugated estrogens are excreted in bile, urine, and feces (Raftogianis et al., 2000). Nevertheless, approximately 65% of estradiol is recovered in bile, 10% -15% is found in feces while a significant proportion of estrogens is reabsorbed into the circulation (Adlercreutz and Jarvenpaa, 1982; Adlercreutz and Martin, 1980; Sandberg and Slaunwhite, 1957). This reabsorption of hepatically conjugated estrogens is mediated by deconjugation processes by gut bacteria with ß-glucuronidase activity such as the *Clostridium leptum* and *Clostridium coccoides* cluster, and the *Escherichia/Shigella* bacterial group (Fernandez and Reina-Perez, 2018; Gloux et al., 2011; Kwa et al., 2016). Thus, a deconjugating enzyme enriched estrobolome could promote reabsorption of free estrogens thereby increasing estrogen levels, which may contribute to breast tissue changes (Fernandez and Reina-Perez, 2018; Kwa et al., 2016).

In the current study, we also found a significant association between the anxiety subdomain of the DRSP and increased LPS load in the plasma. These findings extent our previous results that increased IgA responses to *P. aeruginosa* at the end of term pregnancy are associated with anxiety 4-6 weeks after delivery (Roomruangwong et al., 2017a). It is plausible that the above associations between increasing LPS load and symptom domains including anxiety and physio-somatic symptoms may be explained by low-grade immune-inflammatory responses induced by LPS activation of the Toll-Like-Receptor (TLR)-4 complex, a receptor of the innate immune system which upon activation causes release of reactive oxygen species, cytokines and nitric oxide (Lucas and Maes, 2013). This theory is corroborated by findings that increased root canal endotoxin in subjects with chronic apical

periodontitis is associated with increased nitro-oxidative stress and depressive symptoms (Gomes et al., 2018). Moreover, repeated and intermittent administration of LPS may induce depressive-like behaviors in the rodent in association with increased microglial activation and increased levels of nuclear factor-kB, superoxide and cytokine production, lowered tryoptophan and increased neurotoxic tryptophan catabolites (Kubera et al., 2013; Rodrigues et al., 2018). Administration of LPS to humans not only induces the levels of pro- and anti-inflammatory cytokines, but also lowers mood, and induces anxiety and social disconnection (Eisenberger et al., 2010; Grigoleit et al., 2011). All in all, our findings may indicate that variations in LPS of Gram-negative bacteria during the menstrual cycle with peaks at the end of day 28 of the menstrual cycle could play a pathophysiological role in premenstrual and PeriMS symptoms.

The third major finding of our study is that many, but not all, associations between Δ IgA responses to LPS and symptom domains disappeared after introducing progesterone and changes in progesterone levels in the GEE analyses, although the effects of *P. putida* on physio-somatic symptoms and breast-craving remained significant. This may be explained as the increments in IgA responses to LPS are largely predicted by increasing progesterone levels coupled with lowered steady state progesterone levels or a relative increase in oestradiol steady-state levels versus those of progesterone. Progesterone receptors are present in colon epithelial cells where they interact with progesterone and modulate the colonic transit time (Guarino et al., 2011). The colonic transit time is longer during the luteal phase (high progesterone) when compared to the follicular phase (low progesterone) (Jung et al., 2003; Wald et al., 1981). Progesterone also impairs smooth muscle contraction (Li et al., 2012; Xiao et al., 2009) and downregulates the barrier function of tight junctions which may contribute to cytoskeletal remodeling (Someya et al., 2013) in uterine endometrium. Progesterone promotes endometrial remodeling via modifications of actin fibers architecture,

which leads to cell membrane reshaping and movement (Pfaendtner et al., 2010; Shortrede et al., 2018; Svitkina, 2018). Moreover, progesterone controls actin polymerization, branching, and focal adhesion complex formation via Membrane-Organizing Extension Spike protein (Moesin), and focal adhesion kinase (FAK) (Sanchez et al., 2013; Shortrede et al., 2018). Adhesion assembly in uterine epithelial cells is regulated by progesterone while oestrogens concentrate talin and paxillin (Kaneko et al., 2009). Progesterone also induces dickkopf homologue 1 (DKK1) and forkhead box O1 (FOXO1), resulting in inhibition of Wnt/β-catenin signaling in the human endometrium (Wang et al., 2009). Moreover, oestrogens play a role in the tight junctions in the gut by decreasing zonula occludens 1 mRNA and protein expression thereby increasing gut permeability (Zhou et al., 2017). As such, increasing progesterone levels in the luteal phase may possibly affect the tight and adherens junctions of the paracellular pathway, the transcellular (talin) and the vascular barrier (catenin) pathways, which all protect against bacterial translocation (Maes et al., 2019). Moreover, lowered steady-state levels of progesterone may be associated with upregulated progesterone receptors (Saracoglu et al., 1985), which may increase sensitivity of for example colon muscle cells to progesterone (Cheng et al., 2008). As a consequence, relatively small increments in progesterone coupled with upregulated progesterone receptors and relatively higher oestradiol steady-state levels could contribute to increased gut permeability and, in turn, bacterial translocation thereby stimulating IgA production 5-7 days later (Cerutti, 2008). As such, changes in progesterone during the menstrual cycle coupled with a relative corpus luteum insufficiency (Roomruangwong et al., 2019) may drive menstrual cycle-associated increments in IgA responses to LPS and thus PMS/PeriMS symptoms. Nevertheless, no studies have examined the effects of sex hormones on the gut tight and adherens junctions and the gut vascular barrier.

The current findings should be interpreted within its limitations. First, it would have been even more interesting if we had measured the gut microbiome and stool assays including indicants of gut dysbiosis (Simeonova et al., 2018). Second, we enrolled a relatively small sample to detect associations between the biomarkers and PMS or PeriMS classifications. Nevertheless, the strengths of the study are that we examined associations over time between biomarker measurements and clinical data during the menstrual cycle. Interestingly, while the repeated measurements in IgA responses were significantly associated with those in symptoms, no associations could be detected between LPS data and any of the diagnoses of PMS or PeriMS. This indicates that research in PMS or PeriMS should always examine the associations over time between biomarkers and affective, fatigue and physiosomatic symptoms because a diagnosis of PMS/PeriMS is a limited aspect of peri-menstrual symptoms that cannot capture those assocociations over time.

In conclusion, during the menstrual cycle there are significant changes in IgA responses to LPS of Gram-negative bacteria with peaks in the late luteal phase and lows from week 1 to ovulation. Increments in progesterone during the menstrual cycle superimposed on lowered steady-state progesterone levels during the cycle may drive those menstrual-cycle-associated alterations in IgA responses to LPS thereby contributing to severity of peri-menstrual, physio-somatic, anxiety, food cravings and breast swelling symptoms.

Authorships

CR and MM made the design of the study. CR recruited and screened the participants. MM performed statistical analyses. AC contributed in a meaningful way to the intellectual content of this paper. All authors agreed upon the final version of the paper.

Acknowledgements

Conflict of interest

The authors have no conflict of interest with any commercial or other association in connection with the submitted article.

References

Adlercreutz, H., Jarvenpaa, P., 1982. Assay of estrogens in human feces. J Steroid Biochem 17, 639-645.

Adlercreutz, H., Martin, F., 1980. Biliary excretion and intestinal metabolism of progesterone and estrogens in man. J Steroid Biochem 13, 231-244.

American College of Obstetricians and Gynecologists, 2014. Guidelines for Women's Health Care: A Resource Manual. American College of Obstetricians and Gynecologists, Washington, DC.

Biggs, W.S., Demuth, R.H., 2011. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician 84, 918-924.

Boots, C.E., Jungheim, E.S., 2015. Inflammation and Human Ovarian Follicular Dynamics. Semin Reprod Med 33, 270-275.

Boskey, E.R., Cone, R.A., Whaley, K.J., Moench, T.R., 2001. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod 16, 1809-1813.

Boskey, E.R., Telsch, K.M., Whaley, K.J., Moench, T.R., Cone, R.A., 1999. Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. Infect Immun 67, 5170-5175.

Brantsaeter, A.L., Myhre, R., Haugen, M., Myking, S., Sengpiel, V., Magnus, P., Jacobsson, B., Meltzer, H.M., 2011. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. Am. J. Epidemiol. 174, 807-815.

Brown, C.T., Davis-Richardson, A.G., Giongo, A., Gano, K.A., Crabb, D.B., Mukherjee, N., Casella, G., Drew, J.C., Ilonen, J., Knip, M., Hyoty, H., Veijola, R., Simell, T., Simell, O., Neu, J., Wasserfall, C.H., Schatz, D., Atkinson, M.A., Triplett, E.W., 2011. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PloS one 6, e25792.

Cerutti, A., 2008. The regulation of IgA class switching. Nature reviews. Immunology 8, 421-434.

Chen, C., Song, X., Wei, W., Zhong, H., 2017. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases 8, 875.

Cheng, L., Pricolo, V., Biancani, P., Behar, J., 2008. Overexpression of progesterone receptor B increases sensitivity of human colon muscle cells to progesterone. American journal of physiology. Gastrointestinal and liver physiology 295, G493-502.

Deuster, P.A., Adera, T., South-Paul, J., 1999. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 8, 122-128.

Dickerson, L.M., Mazyck, P.J., Hunter, M.H., 2003. Premenstrual syndrome. Am Fam Physician 67, 1743-1752.

Edwards, S.M., Cunningham, S.A., Dunlop, A.L., Corwin, E.J., 2017. The Maternal Gut Microbiome During Pregnancy. MCN. Am. J. Matern. Child Nurs. 42, 310-317.

Eisenberger, N.I., Inagaki, T.K., Mashal, N.M., Irwin, M.R., 2010. Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain, behavior, and immunity 24, 558-563.

Endicott, J., Nee, J., Harrison, W., 2006. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 9, 41-49.

Fernandez, M.F., Reina-Perez, I., 2018. Breast Cancer and Its Relationship with the Microbiota 15.

Gajer, P., Brotman, R.M., Bai, G., Sakamoto, J., Schutte, U.M., Zhong, X., Koenig, S.S., Fu, L., Ma, Z.S., Zhou, X., Abdo, Z., Forney, L.J., Ravel, J., 2012. Temporal dynamics of the human vaginal microbiota. Sci Transl Med 4, 132ra152.

Galley, J.D., Bailey, M.T., 2014. Impact of stressor exposure on the interplay between commensal microbiota and host inflammation. Gut Microbes 5, 390-396.

Garcia-Gomez, E., Gonzalez-Pedrajo, B., Camacho-Arroyo, I., 2013. Role of sex steroid hormones in bacterial-host interactions. Biomed. Res. Int. 2013, 928290.

Gareau, M.G., Silva, M.A., Perdue, M.H., 2008. Pathophysiological mechanisms of stress-induced intestinal damage. Curr Mol Med 8, 274-281.

Gloux, K., Berteau, O., El Oumami, H., Beguet, F., Leclerc, M., Dore, J., 2011. A metagenomic beta-glucuronidase uncovers a core adaptive function of the human intestinal microbiome. Proc Natl Acad Sci U S A 108 Suppl 1, 4539-4546.

Gomes, C., Martinho, F.C., Barbosa, D.S., Antunes, L.S., Povoa, H.C.C., Baltus, T.H.L., Morelli, N.R., Vargas, H.O., Nunes, S.O.V., Anderson, G., Maes, M., 2018. Increased Root Canal Endotoxin Levels are Associated with Chronic Apical Periodontitis, Increased Oxidative and Nitrosative Stress, Major Depression, Severity of Depression, and a Lowered Quality of Life. Molecular neurobiology 55, 2814-2827.

Grigoleit, J.S., Kullmann, J.S., Wolf, O.T., Hammes, F., Wegner, A., Jablonowski, S., Engler, H., Gizewski, E., Oberbeck, R., Schedlowski, M., 2011. Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PloS one 6, e28330.

Guarino, M., Cheng, L., Cicala, M., Ripetti, V., Biancani, P., Behar, J., 2011. Progesterone receptors and serotonin levels in colon epithelial cells from females with slow transit constipation. Neurogastroenterol Motil 23, 575-e210.

Hamer, H.M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F.J., Brummer, R.J., 2008. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27, 104-119.

Heitkemper, M.M., Cain, K.C., Jarrett, M.E., Burr, R.L., Hertig, V., Bond, E.F., 2003. Symptoms across the menstrual cycle in women with irritable bowel syndrome. Am J Gastroenterol 98, 420-430.

Huang, J.H., Douglas, A.E., 2015. Consumption of dietary sugar by gut bacteria determines Drosophila lipid content. Biol Lett 11, 20150469.

Inan, M.S., Rasoulpour, R.J., Yin, L., Hubbard, A.K., Rosenberg, D.W., Giardina, C., 2000. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology 118, 724-734.

Jung, H.K., Kim, D.Y., Moon, I.H., 2003. Effects of gender and menstrual cycle on colonic transit time in healthy subjects. Korean J Intern Med 18, 181-186.

Kaneko, Y., Lecce, L., Murphy, C.R., 2009. Ovarian hormones regulate expression of the focal adhesion proteins, talin and paxillin, in rat uterine luminal but not glandular epithelial cells. Histochem Cell Biol 132, 613-622.

Keane, F.E., Ison, C.A., Taylor-Robinson, D., 1997. A longitudinal study of the vaginal flora over a menstrual cycle. Int J STD AIDS 8, 489-494.

Keightley, P.C., Koloski, N.A., Talley, N.J., 2015. Pathways in gut-brain communication: evidence for distinct gut-to-brain and brain-to-gut syndromes. Aust N Z J Psychiatry 49, 207-214.

Kleiman, S.C., Watson, H.J., Bulik-Sullivan, E.C., Huh, E.Y., Tarantino, L.M., Bulik, C.M., Carroll, I.M., 2015. The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology. Psychosom Med 77, 969-981.

Koren, O., Goodrich, J.K., Cullender, T.C., Spor, A., Laitinen, K., Backhed, H.K., Gonzalez, A., Werner, J.J., Angenent, L.T., Knight, R., Backhed, F., Isolauri, E., Salminen, S., Ley, R.E., 2012. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 150, 470-480.

Kubera, M., Curzytek, K., Duda, W., Leskiewicz, M., Basta-Kaim, A., Budziszewska, B., Roman, A., Zajicova, A., Holan, V., Szczesny, E., Lason, W., Maes, M., 2013. A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months. Brain, behavior, and immunity 31, 96-104.

Kwa, M., Plottel, C.S., Blaser, M.J., Adams, S., 2016. The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. J Natl Cancer Inst 108.

Leitao-Goncalves, R., Carvalho-Santos, Z., Francisco, A.P., Fioreze, G.T., Anjos, M., Baltazar, C., Elias, A.P., Itskov, P.M., Piper, M.D.W., Ribeiro, C., 2017. Commensal bacteria and essential amino acids control food choice behavior and reproduction 15, e2000862.

Li, C.P., Ling, C., Biancani, P., Behar, J., 2012. Effect of progesterone on colonic motility and fecal output in mice with diarrhea. Neurogastroenterol Motil 24, 392-e174.

Longstreth, G.F., Thompson, W.G., Chey, W.D., Houghton, L.A., Mearin, F., Spiller, R.C., 2006. Functional bowel disorders. Gastroenterology. 130, 1480-1491.

Lucas, K., Maes, M., 2013. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Molecular neurobiology 48, 190-204.

Mack, I., Cuntz, U., Gramer, C., Niedermaier, S., Pohl, C., Schwiertz, A., Zimmermann, K., Zipfel, S., Enck, P., Penders, J., 2016. Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints. Sci Rep 6, 26752.

Maes, M., Kubera, M., Leunis, J.C., 2008. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinol. Lett. 29, 117-124.

Maes, M., Kubera, M., Leunis, J.C., Berk, M., 2012. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J. Affect. Disord. 141, 55-62.

Maes, M., Kubera, M., Leunis, J.C., Berk, M., Geffard, M., Bosmans, E., 2013a. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr Scand 127, 344-354.

Maes, M., Leunis, J.C., 2008. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett 29, 902-910.

Maes, M., Leunis, J.C., Geffard, M., Berk, M., 2014. Evidence for the existence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with and without abdominal discomfort (irritable bowel) syndrome. Neuro Endocrinol Lett 35, 445-453.

Maes, M., Mihaylova, I., Leunis, J.C., 2007. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J Affect Disord 99, 237-240.

Maes, M., Ringel, K., Kubera, M., Anderson, G., Morris, G., Galecki, P., Geffard, M., 2013b. In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation. J Affect Disord 150, 223-230.

Maes, M., Sirivichayakul, S., Kanchanatawan, B., Vojdani, A., 2019. Breakdown of the Paracellular Tight and Adherens Junctions in the Gut and Blood Brain Barrier and Damage to the Vascular Barrier in Patients with Deficit Schizophrenia. Preprints 2019020182.

Martin-Subero, M., Anderson, G., Kanchanatawan, B., Berk, M., Maes, M., 2016. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. CNS Spectr 21, 184-198.

Mayer, E.A., Savidge, T., Shulman, R.J., 2014. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 146, 1500-1512.

Moore, J., Barlow, D., Jewell, D., Kennedy, S., 1998. Do gastrointestinal symptoms vary with the menstrual cycle? Br. J. Obstet. Gynaecol. 105, 1322-1325.

Mulak, A., Taché, Y., 2010. Sex difference in irritable bowel syndrome: do gonadal hormones play a role? Gastroenterol. Pol. 17, 89–97.

Mulak, A., Tache, Y., Larauche, M., 2014. Sex hormones in the modulation of irritable bowel syndrome. World J. Gastroenterol. 20, 2433-2448.

Narushima, S., Itoh, K., Sankai, T., Takasaka, M., Otani, I., Yoshikawa, Y., 1997. Changes in normal vaginal flora of African green monkeys (Cercopithecus aethiops) during the menstrual cycle. Exp Anim 46, 47-52.

Pfaendtner, J., Lyman, E., Pollard, T.D., Voth, G.A., 2010. Structure and dynamics of the actin filament. J Mol Biol 396, 252-263.

Plottel, C.S., Blaser, M.J., 2011. Microbiome and malignancy. Cell Host Microbe 10, 324-335.

Profet, M., 1993. Menstruation as a defense against pathogens transported by sperm. Q Rev Biol 68, 335-386.

Pryde, S.E., Duncan, S.H., Hold, G.L., Stewart, C.S., Flint, H.J., 2002. The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 217, 133-139.

Qiao, M., Zhang, H., Liu, H., Luo, S., Wang, T., Zhang, J., Ji, L., 2012. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample in China. Eur J Obstet Gynecol Reprod Biol. 162, 83-86.

Raftogianis, R., Creveling, C., Weinshilboum, R., Weisz, J., 2000. Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr, 113-124.

Rodrigues, F.T.S., de Souza, M.R.M., Lima, C.N.C., da Silva, F.E.R., Costa, D., Dos Santos, C.C., Miyajima, F., de Sousa, F.C.F., Vasconcelos, S.M.M., Barichello, T., Quevedo, J., Maes, M., de Lucena, D.F., Macedo, D., 2018. Major depression model induced by repeated and intermittent lipopolysaccharide administration: Long-lasting behavioral, neuroimmune and neuroprogressive alterations. Journal of psychiatric research 107, 57-67.

Roomruangwong, C., Anderson, G., Berk, M., Stoyanov, D., Carvalho, A.F., Maes, M., 2018 A neuro-immune, neuro-oxidative and neuro-nitrosative model of prenatal and postpartum depression. Prog Neuropsychopharmacol Biol Psychiatry 81, 262-274.

Roomruangwong, C., Carvalho , A.F., Comhaire, F., Maes, M., 2019. Lowered Plasma Steady-State Levels of Progesterone Combined with Declining Progesterone Levels During the Luteal Phase Predict Peri-Menstrual Syndrome and Its Major Subdomains. Preprints 2019010085.

Roomruangwong, C., Kanchanatawan, B., Sirivichayakul, S., Anderson, G., Carvalho, A.F., Duleu, S., Geffard, M., Maes, M., 2017a. IgA / IgM responses to Gram-negative bacteria are not associated with prenatal depression, but with physio-somatic symptoms and activation of the tryptophan catabolite pathway at the end of term and postnatal anxiety. CNS Neurol Disord Drug Targets [Epub ahead of print].

Roomruangwong, C., Kanchanatawan, B., Sirivichayakul, S., Anderson, G., Carvalho, A.F., Duleu, S., Geffard, M., Maes, M., 2017b. IgM-mediated autoimmune responses to oxidative specific epitopes, but not nitrosylated adducts, are significantly decreased in pregnancy: association with bacterial translocation, perinatal and lifetime major depression and the tryptophan catabolite (TRYCAT) pathway. Metab Brain Dis [Epub ahead of print].

Sanchez, A.M., Flamini, M.I., Genazzani, A.R., Simoncini, T., 2013. Effects of progesterone and medroxyprogesterone on actin remodeling and neuronal spine formation. Mol Endocrinol 27, 693-702.

Sandberg, A.A., Slaunwhite, W.R., Jr., 1957. Studies on phenolic steroids in human subjects. II. The metabolic fate and hepato-biliary-enteric circulation of C14-estrone and C14-estradiol in women. J Clin Invest 36, 1266-1278.

Saracoglu, O.F., Aksel, S., Yeoman, R.R., Wiebe, R.H., 1985. Endometrial estradiol and progesterone receptors in patients with luteal phase defects and endometriosis. Fertil. Steril. 43, 851-855.

Sasaki, H., Kawamura, K., Kawamura, T., Odamaki, T., Katsumata, N., Xiao, J.Z., Suzuki, N., Tanaka, M., 2018. Distinctive subpopulations of the intestinal microbiota are present in women with unexplained chronic anovulation. Reprod Biomed Online.

Schwebke, J.R., Weiss, H., 2001. Influence of the normal menstrual cycle on vaginal microflora. Clin Infect Dis 32, 325.

Sgambato, D., Miranda, A., Ranaldo, R., Federico, A., Romano, M., 2017. The Role of Stress in Inflammatory Bowel Diseases. Curr Pharm Des 23, 3997-4002.

Shacklett, B.L., Greenblatt, R.M., 2011. Immune responses to HIV in the female reproductive tract, immunologic parallels with the gastrointestinal tract, and research implications. Am J Reprod Immunol 65, 230-241.

Shortrede, J.E., Montt-Guevara, M.M., Pennacchio, G., Finiguerra, M., Giannini, A., Genazzani, A.D., Simoncini, T., 2018. Ulipristal Acetate Interferes With Actin Remodeling Induced by 17beta-Estradiol and Progesterone in Human Endometrial Stromal Cells. Front Endocrinol (Lausanne) 9, 350.

Simeonova, D., Ivanovska, M., Murdjeva, M., Carvalho, A.F., Maes, M., 2018. Recognizing the Leaky Gut as a Trans-diagnostic Target for Neuroimmune Disorders Using Clinical Chemistry and Molecular Immunology Assays. Current topics in medicinal chemistry 18, 1641-1655.

Slyepchenko, A., Maes, M., Jacka, F.N., Köhler, C.A., Barichello, T., McIntyre, R.S., Berk, M., Grande, I., Foster, J.A., Vieta, E., Carvalho, A.F., 2017. Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities. Psychother Psychosom 86, 31-46.

Slyepchenko, A., Maes, M., Machado-Vieira, R., Anderson, G., Solmi, M., Sanz, Y., Berk, M., Kohler, C.A., Carvalho, A.F., 2016. Intestinal Dysbiosis, Gut Hyperpermeability and

Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes. Curr Pharm Des 22, 6087-6106.

Someya, M., Kojima, T., Ogawa, M., Ninomiya, T., Nomura, K., Takasawa, A., Murata, M., Tanaka, S., Saito, T., Sawada, N., 2013. Regulation of tight junctions by sex hormones in normal human endometrial epithelial cells and uterus cancer cell line Sawano. Cell Tissue Res 354, 481-494.

Stumpf, R.M., Wilson, B.A., Rivera, A., Yildirim, S., Yeoman, C.J., Polk, J.D., White, B.A., Leigh, S.R., 2013. The primate vaginal microbiome: comparative context and implications for human health and disease. Am J Phys Anthropol 152, 119-134.

Svitkina, T.M., 2018. Ultrastructure of the actin cytoskeleton. Curr Opin Cell Biol 54, 1-8.

Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031.

van de Wouw, M., Schellekens, H., 2017. Microbiota-Gut-Brain Axis: Modulator of Host Metabolism and Appetite 147, 727-745.

Wald, A., Van Thiel, D.H., Hoechstetter, L., Gavaler, J.S., Egler, K.M., Verm, R., Scott, L., Lester, R., 1981. Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology 80, 1497-1500.

Wang, Y., Hanifi-Moghaddam, P., Hanekamp, E.E., Kloosterboer, H.J., Franken, P., Veldscholte, J., van Doorn, H.C., Ewing, P.C., Kim, J.J., Grootegoed, J.A., Burger, C.W., Fodde, R., Blok, L.J., 2009. Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 15, 5784-5793.

Whitehead, W.E., Cheskin, L.J., Heller, B.R., Robinson, J.C., Crowell, M.D., Benjamin, C., Schuster, M.M., 1990. Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology 98, 1485–1489.

Xiao, Z.L., Biancani, P., Behar, J., 2009. Effects of progesterone on motility and prostaglandin levels in the distal guinea pig colon. American journal of physiology. Gastrointestinal and liver physiology 297, G886-893.

Zhu, B.T., Conney, A.H., 1998. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19, 1-27.

Figure 1. Mean (SE) values of the IgA responses to LPS of 6 Gram-negative bacteria during

the menstrual cycle.

T1: day 7, T2: day 14, T3: day 21 and T4: day 28.

All mean values are shown as z scores of the Δ IgA values (actual value − value one week

earlier).

Table 1 Definition of four different diagnoses used in the current study to diagnose "premenstrual" syndrome

Diagnostic Label	Abbreviation	Definition
Premenstrual syndrome (American College of Obstetricians and Gynecologists)	ACOG	Subjects report 1 or more of the following affective and somatic symptoms at day -5 before menses in each of 3 prior menstrual cycles Affective — Somatic Depression — Breast tenderness Angry outbursts — Abdominal bloating Irritability — Headache Anxiety — Swelling of extremities Confusion Social withdrawal Symptoms relieved within 4 days after menses onset without recurrence until at least cycle day 13. Symptoms present in absence of any pharmacologic therapy, hormone ingestion, or drug or alcohol use. Symptoms occur reproducibly during 2 cycles of prospective recording Subjects suffer from identifiable dysfunction in social or economic performance
Premenstrual syndrome	PMS	PMS: subjects who scored $\geq$ 70 on the total Daily Record of Severity of Problems (DRSP) score during day 24-28 of menstrual cycle, and in addition there is a difference of at least 30% in DRSP scores between pre (late luteal phase day 24-28) and post (mid follicular day 6-10) menstrual phases
Peri-menstrual Syndrome	PeriMS	Sum DRSP day 1+ day 2 + day 24 to 28 $\geq$ 307 (0.666 percentile value)
Menstrual Cycle associated Symptoms	MCAS	Sum of all DRSP scores from day 1 to day 28 $\geq$ 1,050 (0.666 percentile value)

DRSP: Daily Record of Severity of Problems

Table 2 Demographic and clinical data is women with and without pre-menstrual syndrome (PMS)

Variables	No PMS	PMS	F/X^2	df	p
Age (years)	29.8 (7.3)	32.3 (6.9)	1.22	1/39	0.276
Education (years)	16.2 (1.2)	15.8 (1.6)	1.15	1/39	0.290
Age menarche (years)	13.0 (1.3)	12.6 (1.2)	0.92	1/39	0.345
Length cycle (days)	28.0 (1.9)	27.3 (5.3)	0.28	1/39	0.601
Duration menses (days)	4.5 (1.3)	4.9 (1.6)	0.68	1/39	0.416
BMI (kg/m^2)	21.8 (3.6)	22.5 (3.8)	0.43	1/39	0.416
DRSP (sum of all items during 28 days)	878.4 (210.5)	974.5 (204.0)	2.15	1/39	0.151

All results are shown as mean (SD)

PMS: diagnosis according to the criteria of the American College of Obstetricians and Gynecologists

DRSP: Daily Record of Severity of Problems

BMI: body mass index

Table3 Measurements of Daily Record of Severity of Problems (DRSP) and subdomains, and plasma levels of oestradiol and progesterone during the menstrual cycle

Variables	T1[1]	T2[2]	T3[3]	T4[4]	Wald X^2	df	p
DRSP total score (daily values)	31.2 (1.8)[2,4]	27.4 (0.8)[1,3,4]	30.9 (1.4)[2,4]	39.8 (3.5)[1,2,3]	31.02	3	<0.001
Depression score	11.7 (0.7)[2]	10.2 (0.3)[1,4]	11.1 (0.6)[4]	14.5 (1.4)[2,3]	22.95	3	<0.001
Fatigue & physio-somatic symptoms	8.0 (0.5)[2,4]	7.0 (0.3)[1,3,4]	8.0 (0.5)[2,4]	10.4 (1.0)[1,2,3]	28.26	3	<0.001
Breast & craving score	5.2 (0.4)[4]	4.6 (0.2)[3,4]	5.8 (0.4)[2,4]	7.4 (0.7)[1,2,3]	28.35	3	<0.001
Anxiety score	6.5 (0.5)[4]	5.9 (0.3)[4]	6.4 (0.4)[4]	7.8 (0.6)[1,2,3]	17.58	3	<0.001
Oestradiol (pmol/L)	289.5 (43.9)[2,3]	606.4 (75.2)[1,4]	597.8 (44.2)[1,4]	281.9 (25.9)[2,3]	68.16	3	<0.001
Progesterone (nmol/L)	0.54 (0.05)[2,3,4]	3.55 (0.95)[1,3,4]	34.65 (4.22)[1,2,4]	11.45 (2.03)[1,2,3]	102.39	3	<0.001

Table 4 Results of generalized estimating equation (GEE) analysis, i.e. effects of time on the Δ IgA responses directed against LPS of 6 Gram-negative bacteria as dependent variables.

Variables	T1[1]	T2[2]	T3[3]	T4[4]	Wald X^2	df	p
Δ *Citrobacter koseri*	-0.579 (0.149)[3,4]	-0.295 (0.141)[3,4]	0.250 (0.137)[1,2]	0.624 (0.129)[1,2]	33.83	3	<0.001
Δ *Pseudomonas putida*	-0.291 (0.193)[4]	-0.339 (0.109)[3,4]	0.023 (0.111)[2,4]	0.628 (0.152)[1,2,3]	30.71	3	<0.001
Δ *Klebsiella pneumoniae*	-0.223 (0.127)[4]	-0.373 (0.174)[4]	0.175 (0.159)	0.422 (0.133)[1,2]	13.88	3	0.003
Δ *Hafnia alvei*	-0.351 (0.130)[4]	-0.576 (0.128)[3,4]	-0.059 (0.099)[2,4]	0.987 (0.143)[1,2,3]	57.47	3	<0.001
Δ *Pseudomonas aeruginosa*	-0.218 (0.145)[4]	-0.342 (0.171)[4]	-0.118 (0.120)[4]	0.596 (0.149)[1,2,3]	17.26	3	0.001
Δ *Morganella morganii*	-0.260 (0.152)[4]	-0.366 (0.133)[4]	-0.293 (0.110)[4]	0.936 (0.135)[1,2,3]	61.88	3	<0.001
Sum of all Δ values	-1.922 (0.711)[4]	-2.293 (0.671)[3,4]	-0.013 (0.606)[2,4]	3.960 (0.757)[1,2,3]	34.09	3	<0.001

Results are shown as mean (±SE) and as z scores

Δ: computed as actual value – values one week earlier

Table 5 Results of generalized estimating equation (GEE) analysis with the Daily Record of Severity of Problems (DRSP) score and subdomains as dependent variables.

Dependent variables	Explanatory variables	Wald X^2	df	p
DRSP total score	Δ *Hafnia alvei*	6.51	1	0.011
	Δ *Morganella morganii*	4.76	1	0.029
	Δ *Pseudomonas putida*	4.00	1	0.046
Fatigue & physio-somatic symptoms	Δ *H. alvei*	4.88	1	0.027
	Δ *M. morganii*	5.05	1	0.025
	Δ *P. putida*	8.84	1	0.003
Breast & craving symptoms	Δ *H. alvei*	11.53	1	0.001
	Δ *M. morganii*	7.81	1	0.005
	Δ *P. putida*	10.40	1	0.001
	Δ *Citrobacter koseri*	4.52	1	0.033
Anxiety symptoms	Δ *H. alvei*	8.40	1	0.004
DRSP total score	Δ *H. alvei*	0.59	1	0.442
	Lag Progesterone	7.87	1	0.005
	Progesterone T2+T3+T4	21.02	1	<0.001
Fatigue & physio-somatic symptoms	Δ *P. putida*	5.41	1	0.020
	Lag Progesterone	6.85	1	0.009
	Progesterone T2+T3+T4	8.87	1	0.003
Breast & craving symptoms	Δ *H. alvei*	3.68	1	0.055
	Lag Progesterone	5.16	1	0.023
	Progesterone T2+T3+T4	7.33	1	0.007
	Δ *P. putida*	5.73	1	0.017

	Lag Progesterone	6.98	1	0.008
	Progesterone T2+T3+T4	7.71	1	0.005
Anxiety symptoms	Δ *H. alvei*	1.24	1	0.266
	Lag Progesterone	5.93	1	0.015
	Progesterone T2+T3+T4	6.26	1	0.012

Lag progesterone: 1 week lagged values

Δ: computed as actual value – values one week earlier

Table 6 Results of generalized estimating equation (GEE) analysis with the IgA directed to LPS of 6 gram-negative bacteria as dependent variables.

Dependent variables	Explanatory variables	Wald $X2$	df	P
Δ *Hafnia alvei*	Lag progesterone	27.55	1	<0.001
	Progesterone T2+T3+T4	30.97	1	<0.001
	Δ Progesterone	8.41	1	0.004
Δ *Morganella morganii*	Lag progesterone	31.82	1	<0.001
	Progesterone T2+T3+T4	37.57	1	<0.001
Δ *Pseudomonas putida*	Lag progesterone	22.40	1	<0.001
	Progesterone T2+T3+T4	11.28	1	0.001
	Δ Progesterone	7.50	1	0.006
Δ *Citobacter koseri*	Lag progesterone	17.15	1	<0.001
	Progesterone T2+T3+T4	15.78	1	<0.001
	Δ Progesterone	9.50	1	0.002
Δ *Pseudomonas aeruginosa*	Lag progesterone	10.58	1	0.001
	Progesterone T2+T3+T4	8.23	1	0.004
	Δ Progesterone	6.22	1	0.013
Δ *Klebsiella pneumoniae*	Lag progesterone	13.05	1	<0.001
	Progesterone T2+T3+T4	10.96	1	0.001

Lag progesterone: 1 week lagged values

Δ: computed as actual value – values one week earlier